EGFR and non-small cell lung carcinoma: Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors (TKIs) are frontline therapy for advanced or metastatic non-small cell lung cancer (NSCLC) with sensitizing EGFR mutations such as exon 19 deletion or exon 21 L858R mutation [3].